mRNA therapeutics pioneer expanding beyond COVID into cancer and rare diseases
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
Moderna will enter into a five-year strategic agreement with the government of Mexico to supply its respiratory vaccine portfolio and transfer technology to Liomont, a Mexican pharmaceutical company.
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for its investigational seasonal influenza vaccine, mRNA-1010.
Moderna to pay up to $2.25B to end mRNA vaccine patent dispute
Moderna has agreed to pay up to $2.25 billion to Arbutus Biopharma and Roivant subsidiary Genevant Sciences to settle a patent dispute over mRNA vaccine technology.
Moderna stock surges as FDA reverses course, agrees to review new flu shot
The FDA has agreed to review Moderna's new flu shot after previously declining, causing a significant surge in the company's stock price.
Get notified when new signals are published for this company.